Medicare to boost payment for certain diagnostic imaging agents
Radiology Business
NOVEMBER 5, 2024
CMS is moving forward with a proposal to issue separate reimbursement for radiopharmaceuticals—a change long lobbied for by the imaging industry.
Diagnostic Diagnostic Imaging Radiopharmaceuticals 
Targeted radiopharmaceuticals offer new hope for longer 'healthspans'
AuntMinnie
MARCH 15, 2024
An emerging field of precision radiopharmaceuticals brings new optimism to this mission, revolutionizing cancer care. Precision radiopharmaceuticals accurately target tumors while minimizing damage to healthy tissue. Precision radiopharmaceuticals represent a step toward better, longer lifespans for all.
Philochem and Blue Earth Diagnostics Announce First Three Patients Imaged in Phase 1 Clinical Trial of 68Ga-OncoFAP (68Ga-OncoFAP-DOTAGA) for Diagnostic Imaging in Solid Tumors
Imaging Technology
DECEMBER 6, 2023
and Blue Earth Diagnostics, a Bracco company and recognized leader in the development and commercialization of innovative PET radiopharmaceuticals, today provided additional information regarding a March 2022 licensing and collaboration agreement between Philochem and Blue Earth Diagnostics.
Diagnostic 
105
105 
Assessing a Landmark Change in CMS Reimbursement for Diagnostic Radiopharmaceuticals
Diagnostic Imaging
NOVEMBER 15, 2024
In an interview, SNMMI president Cathy Cutler, PhD, discussed the impact of the recent CMS decision to unbundle reimbursement for diagnostic radiopharmaceuticals costing above $630 a day, calling it a “game changer” decision that will benefit patients, physicians, and the development of new radiopharmaceutical agents.
Blue Earth Diagnostics, a Bracco Company, Appoints Marco Campione as Chief Executive Officer
Imaging Technology
JULY 9, 2024
Campione also joins the Blue Earth Diagnostics Ltd. Board of Directors and will serve as Vice Chair of the Blue Earth Diagnostics Inc. Board of Directors and will serve as Vice Chair of the Blue Earth Diagnostics Inc. Blue Earth Diagnostics, an indirect subsidiary of Bracco Imaging S.p.A., Bracco Imaging S.p.A.,
Diagnostic 105
105 
Blue Earth Therapeutics Announces Promising Results from Preclinical Evaluation of Synergistic Drug Combinations with Radiopharmaceutical 177Lu-rhPSMA-10.1 for Treatment of Prostate Cancer
Imaging Technology
APRIL 10, 2024
an investigational radiohybrid (rh) Prostate-Specific Membrane Antigen-targeted therapeutic radiopharmaceutical, is the lead candidate in Blue Earth Therapeutics’ oncology development program of next generation therapeutic radiopharmaceuticals. 177Lu-rhPSMA-10.1,
Radiometals for diagnostic imaging and theranostics
Open Medscience
AUGUST 8, 2019
Imaging agents can be used to evaluate organ function, detect cancer, measure blood flow and follow metabolic processes. The post Radiometals for diagnostic imaging and theranostics appeared first on Open Medscience.
U.S. FDA Approves Blue Earth Diagnostics’ POSLUMA (Flotufolastat F 18) Injection, First Radiohybrid PSMA-targeted PET Imaging Agent for Prostate Cancer
Imaging Technology
MAY 30, 2023
milla1cf Tue, 05/30/2023 - 19:49 May 30, 2023 — Blue Earth Diagnostics , a Bracco company and recognized leader in the development and commercialization of innovative PET radiopharmaceuticals , today announced U.S. Chief Executive Officer of Blue Earth Diagnostics. Gauden , D.Phil.,
Diagnostic 97
97 
The rise of theranostics: Part 3 -- What is a theranostics center?
AuntMinnie
JUNE 3, 2024
With therapeutic radiopharmaceuticals coming to market quickly and available to smaller institutions around the U.S., My vision of a theranostic center includes a flagship facility that has a PET/CT scanner, a SPECT/CT scanner, and then multiple rooms for infusions of radiopharmaceuticals," Siegel explained.
Nuclear Medicine 106
106 
Blue Earth Diagnostics Announces Additional Results from Phase 3 SPOTLIGHT Trial of Investigational PET Imaging Agent 18F-rhPSMA-7.3 in Biochemical Recurrence of Prostate Cancer
Imaging Technology
MAY 2, 2023
milla1cf Tue, 05/02/2023 - 23:50 May 2, 2023 — Blue Earth Diagnostics , a Bracco company and recognized leader in the development and commercialization of innovative PET radiopharmaceuticals, today announced additional results from its completed Phase 3 SPOTLIGHT trial of 18F-rhPSMA-7.3 Gauden , D.Phil., 18F-rhPSMA-7.3
Diagnostic 98
98 
Blue Earth Diagnostics Announces Addition of POSLUMA (Flotufolastat F 18) Injection to NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) for Prostate Cancer
Imaging Technology
JULY 28, 2023
POSLUMA is widely available through 36 radiopharmacies in the national network of Blue Earth Diagnostics’ commercial U.S. The addition of POSLUMA to the highly respected NCCN Guidelines is a major milestone for Blue Earth Diagnostics,” said David E. Chief Medical Officer of Blue Earth Diagnostics. Teoh, MBBS, MRCP, FRCR, D.Phil.,
Diagnostic 98
98 
The rise of theranostics: Part 5 -- Advice from center administrators
AuntMinnie
JULY 12, 2024
As nuclear medicine therapies gain stature compared to nuclear medicine in diagnostic imaging, hospital administrators may be eyeing the potential of adding theranostics services. At the time, their cancer center served a significant cancer population in the region and maintained robust and ever-expanding PET diagnostics.
Nuclear Medicine 106
106 
Patent Battle Brewing Between Novartis, Lantheus Over Generic Lutathera Radioligand Therapy
Diagnostic Imaging
JANUARY 12, 2024
The FDA has accepted Lantheus' abbreviated new drug application for a generic Lutathera, just months after Novartis announced positive phase 3 data supporting a first-line indication for the radiopharmaceutical in neuroendocrine tumors.
Carolyn J. Anderson, PhD, Receives SNMMI 2024 Georg Charles de Hevesy Nuclear Pioneer Award
Imaging Technology
JUNE 10, 2024
The award was announced by the Society of Nuclear Medicine and Molecular Imaging (SNMMI) during its 2024 Annual Meeting, June 8-11 in Toronto. Her groundbreaking research on radiometal-based agents has paved the way for innovative cancer treatments and diagnostic tools—an enduring contribution to the fight against cancer.”
Nuclear Medicine 104
104 
NorthStar Medical Radioisotopes Provides Updates on Corporate Progress and Upcoming Milestones
Imaging Technology
APRIL 3, 2023
produced, non-uranium based Mo-99 for use in diagnostic imaging. Mr. Merrick continued, “Demand for therapeutic radiopharmaceuticals is increasing rapidly. NorthStar has further deepened and broadened our business platform with the recent establishment of a full-scale radiopharmaceutical CDMO/CMO services unit.
Medical 98
98 
Meet the Minnies 2024 finalists
AuntMinnie
OCTOBER 25, 2024
He earned his medical degree at the University of Alabama School of Medicine and completed a residency in diagnostic radiology at the University of Florida. 7-tesla MRI gets us closer in imaging to our pathology colleagues, and offers many new possibilities for better treatment," he said. He served in the U.S. Elliot Fishman, MD.
Nuclear Medicine 143
143 
A Closer Look at Urinary Activity and PET Radiopharmaceuticals for Prostate Cancer Imaging
Diagnostic Imaging
JUNE 28, 2023
In a recent interview at the Society of Nuclear Medicine and Molecular Imaging (SNMMI) conference in Chicago, Phillip Kuo, M.D.,
Blue Earth Therapeutics Announces Results of Early Clinical and Preclinical Studies of Investigational 177Lu-rhPSMA-10.1 in Treatment of Prostate Cancer
Imaging Technology
JUNE 29, 2023
milla1cf Thu, 06/29/2023 - 21:10 June 29, 2023 — Blue Earth Therapeutics , a Bracco company and emerging leader in the development of innovative next generation therapeutic radiopharmaceuticals, today announced highlights from early clinical and preclinical studies of 177Lu-rhPSMA-10.1 Blue Earth Diagnostics received U.S.
Clinic 98
98 
The Future of Radiotheranostics: A New Frontier in Precision Medicine
Open Medscience
SEPTEMBER 14, 2024
Radiotheranostics offers a precise, personalised approach to cancer treatment by combining diagnostic imaging with targeted therapy The post The Future of Radiotheranostics: A New Frontier in Precision Medicine appeared first on Open MedScience.
What is Radiotheranostics? The Future of Personalised Cancer Diagnosis
Open Medscience
JUNE 22, 2024
Radiotheranostics combines diagnostic imaging and targeted radiotherapy, using radiopharmaceuticals for personalised, precise cancer treatment and improved outcomes. The post What is Radiotheranostics? The Future of Personalised Cancer Diagnosis appeared first on Open MedScience.
Radiotheranostic Treatments: A Guide to Types and Their Clinical Applications
Open Medscience
SEPTEMBER 25, 2024
Radiotheranostic treatments combine diagnostic imaging with targeted radiopharmaceutical therapy, providing personalised cancer care with enhanced precision and effectiveness. The post Radiotheranostic Treatments: A Guide to Types and Their Clinical Applications appeared first on Open MedScience.
Clinic 52
52 
Radiotheranostic Pairs: Bridging Diagnostics and Therapeutics in Cancer
Open Medscience
JUNE 22, 2024
Radiotheranostic Pairs combine diagnostic imaging with targeted radiotherapy, revolutionising personalised cancer treatment through enhanced precision and efficacy. The post Radiotheranostic Pairs: Bridging Diagnostics and Therapeutics in Cancer appeared first on Open MedScience.
Diagnostic 52
52 
New SNMMI President Cathy Cutler, PhD Discusses Current Challenges and Goals for Nuclear Medicine
Diagnostic Imaging
JUNE 9, 2024
shared her perspective on a number of topics affecting nuclear medicine, ranging from isotope availability and reimbursement challenges for diagnostic radiopharmaceuticals to increasing patient interest in PET imaging. In a recent interview, Cathy Cutler, Ph.D.,
GE HealthCare Introduces Groundbreaking Developments in Precision Care at SNMMI24
Imaging Technology
JUNE 20, 2024
More than half of the world’s population is underserved and lacks access to essential health services, and two-thirds have no access to diagnostic imaging. In the hands of clinicians, these tools help make the practice of precision care more accessible and aim to help improve patient outcomes globally.”
Healthcare 104
104 
FDA Grants Fast Track Designation to 64Cu-SAR-bisPSMA PET Agent for Prostate Cancer
Diagnostic Imaging
AUGUST 23, 2024
Currently in phase III trials, the 64Cu-SAR-bisPSMA PET agent reportedly offers a longer half-life and higher tumor uptake than other radiopharmaceuticals for prostate cancer imaging.
Visit TTG Imaging Solutions at ICE 2022
TTG Imaging Solutions
FEBRUARY 17, 2022
About TTG Imaging Solutions TTG Imaging Solutions is your partner for nuclear medicine and molecular imaging solutions that includes equipment sales, nationwide service, parts, turnkey diagnostic imaging, and radiopharmaceuticals.
FDA Clears Automated Dosimetry with the Monte Carlo Method for Radionuclide Therapy
Diagnostic Imaging
OCTOBER 4, 2024
The clearance may facilitate improved standardization and efficiency of dosimetry-guided, theranostic applications of radiopharmaceutical therapy.
Visit TTG Imaging Solutions at ASNC 2021 Virtual Annual Meeting
TTG Imaging Solutions
SEPTEMBER 28, 2021
About TTG Imaging Solutions TTG Imaging Solutions is your partner for nuclear medicine and molecular imaging solutions that includes equipment sales, nationwide service, parts, turnkey diagnostic imaging, and radiopharmaceuticals.
Visit TTG Imaging Solutions at ASTRO 2021 Annual Meeting
TTG Imaging Solutions
OCTOBER 20, 2021
About TTG Imaging Solutions TTG Imaging Solutions is your partner for nationwide equipment sales, service, parts, turnkey diagnostic imaging, and radiopharmaceuticals. Request a meeting with one of our Regional Sales Managers at sales@ttgimagingsolutions.com.
Visit TTG Imaging Solutions at ASNC 2022 Cardiac PET Intensive Virtual Workshop
TTG Imaging Solutions
JANUARY 9, 2022
About TTG Imaging Solutions TTG Imaging Solutions is your partner for nuclear medicine and molecular imaging solutions that includes equipment sales, nationwide service, parts, turnkey diagnostic imaging, and radiopharmaceuticals.
Visit TTG Imaging Solutions at ASNC 2021 Cardiac PET Workshop
TTG Imaging Solutions
OCTOBER 27, 2021
About TTG Imaging Solutions TTG Imaging Solutions is your partner for nuclear medicine and molecular imaging solutions that includes equipment sales, nationwide service, parts, turnkey diagnostic imaging, and radiopharmaceuticals.
Illuminating the Future: Recent Breakthroughs in Nuclear Medicine Advancements (Maharashtra, Raigarh, Sangli, Satara, Sindhudurg, Solapur, Thane, Wardha, Washim, Yavatmal)
Future Teleradiology
NOVEMBER 27, 2023
Teleradiology-India Introduction: Nuclear medicine continues to be at the forefront of cutting-edge technologies, pushing the boundaries of diagnostic and therapeutic capabilities. Revolutionary Radioisotopes: Expanding the Diagnostic Toolkit: Explore the latest developments in novel radioisotopes used in nuclear medicine.
Cancer Radiotheranostics: The Future of Targeted Cancer Therapy
Open Medscience
OCTOBER 19, 2024
Cancer radiotheranostics combines targeted radiotherapy and diagnostic imaging to provide personalised, precise, and effective cancer treatment. The post Cancer Radiotheranostics: The Future of Targeted Cancer Therapy appeared first on Open MedScience.
Breaking Ground: Exploring the Latest Innovations in the Field of Nuclear Medicine (Madhya Pradesh, Bhopal, Raisen, Rajgarh, Sehore, Vidisha, Morena, Sheopur, Bhind, Gwalior, Ashoknagar)
Future Teleradiology
NOVEMBER 21, 2023
Teleradiology & Radiology data for artificial intelligence (AI) Introduction: Nuclear medicine, a dynamic and rapidly evolving field, continues to break new ground in diagnostic and therapeutic approaches. Highlight how this field merges principles of physics with medical applications for both diagnostic and therapeutic purposes.
TTG Imaging Solutions Acquires Digirad Health from Star Equity Holdings
TTG Imaging Solutions
MAY 5, 2023
Enhances TTG’s continued commitment to offer a full spectrum of high-quality and cost-effective service solutions in the cardiology and radiation oncology markets PITTSBURGH, PA (May 5, 2023) – TTG Imaging Solutions, LLC (TTG) announced today the acquisition of Digirad Health, Inc., headquartered in Suwanee, GA. Digirad Health, Inc.
Imaging 52
52 
Martin B. Shirley Executive Vice President Sales, Marketing & Clinical Operations
TTG Imaging Solutions
AUGUST 1, 2023
Martin Shirley was appointed the role of TTG Imaging Solutions Executive Vice President Sales, Marketing & Clinical Operations in April of 2023 as part of TTG Imaging Solutions acquisition of Digirad Health, Inc and its subsidiaries Digirad Diagnostic Imaging, Inc and Digirad Imaging Solution, Inc.
Martin B. Shirley Executive Vice President Sales, Marketing & Clinical Operations
TTG Imaging Solutions
AUGUST 1, 2023
Martin Shirley was appointed the role of TTG Imaging Solutions Executive Vice President Sales, Marketing & Clinical Operations in April of 2023 as part of TTG Imaging Solutions acquisition of Digirad Health, Inc and its subsidiaries Digirad Diagnostic Imaging, Inc and Digirad Imaging Solution, Inc.
Generative AI, radiologist shortages feature in 2024 Minnies
AuntMinnie
NOVEMBER 12, 2024
He earned his medical degree at the University of Alabama School of Medicine and completed a residency in diagnostic radiology at the University of Florida. Beyder played a key role in launching the radiopharmaceutical therapy (RPT) comprehensive center of excellence at WU, BJH, and Siteman Cancer Center last year. from Ukraine.
Radiologist 144
144 
TTG Imaging Solutions, LLC Announces Executive Leadership Changes
TTG Imaging Solutions
NOVEMBER 1, 2021
The organization brought a robust customer base in the mid-west along with a strong group of field service engineers The following executive leadership changes are effective November 1, 2021: Jack Tomayko, Ph.D., Remaining in their current roles are John Nalley, EVP of Equipment Service Operations, and Hunter Forestier, VP of Sales and Marketing.
Additional Results of POSLUMA (Flotufolastat F 18) Performance in Newly Diagnosed, High-risk Prostate Cancer Patients Presented at ASTRO
Imaging Technology
OCTOBER 5, 2023
Chief Executive Officer of Blue Earth Diagnostics. POSLUMA provides physicians with high-quality diagnostic information based on its diagnostic performance even at low PSA levels, high-affinity PSMA binding and low urinary bladder activity. Blue Earth Diagnostics received U.S. Gauden, D.Phil.
Diagnose 52
52 
The rise of theranostics: Part 1 -- Gaining momentum
AuntMinnie
MARCH 26, 2024
Food and Drug Administration's (FDA) approvals of radiopharmaceuticals for neuroendocrine tumors and then for prostate cancer, theranostics has picked up momentum in clinical practice, propelled by encouraging research. Since 2013 we've had several more radiopharmaceutical therapies get FDA approval. Since the U.S.
Nuclear Medicine 122
122 
The rise of theranostics: Part 1 -- Gaining momentum
AuntMinnie
JUNE 20, 2024
Food and Drug Administration's (FDA) approvals of radiopharmaceuticals for neuroendocrine tumors and then for prostate cancer, theranostics has picked up momentum in clinical practice, propelled by encouraging research. Since 2013 we've had several more radiopharmaceutical therapies get FDA approval. Since the U.S.
Let's personalize your content